initial public offerings (IPOs) trading on American exchanges

Thursday, July 3, 2014

Zafgen (ZFGN) began trading on the NASDAQ on 19 June 2014

  • Zafgen (ZFGN), a biotech developing a treatment for severe obesity and hunger-related disorders
  • Offered 5.0 million shares 
  • Zafgen was founded in 2005 in Cambridge, MA. 
  • Leerink Partners and Cowen & Company are the joint bookrunners on the deal.

  • Description

    Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.


    CAMBRIDGE, MA 02142
    United States 

    Key stats and ratios

    Q1 (Mar '14)2013
    Net profit margin--
    Operating margin--
    EBITD margin--
    Return on average assets-45.00%-57.11%
    Return on average equity--

    No comments:

    Post a Comment